Form 4: Cytek Biosciences Director Equity Transaction

Director Vera Imper acquired common stock through RSU vesting and received new equity grants in Cytek Biosciences.

Summary

• Director Vera Imper exercised 43,973 Restricted Stock Units (RSUs) which vested on June 10, 2026.
• Following the transaction, the director holds 59,679 shares of common stock.
• The director was granted 33,333 new RSUs and 18,261 stock options with an exercise price of $4.05.
• The new equity grants are scheduled to vest on the earlier of June 10, 2027, or the 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity management.

Positives

• Director maintains a direct ownership stake in the company, aligning interests with shareholders.

Negatives

• None identified; this is a standard compensatory equity transaction for a board member.

Risks

• Equity-based compensation may lead to future dilution of existing shareholders.

Future Outlook

The director's new equity grants are subject to a one-year vesting schedule, aligning with the company's 2027 annual meeting cycle.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board retention and long-term alignment with corporate performance.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard practices for mid-cap life sciences companies.
• Vesting schedules tied to annual meetings are common governance practices in the industry.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new equity awards.

Next Steps

• Vesting of new equity grants on June 10, 2027.

Key Dates

Keywords

Cytek Biosciences, CTKB, Form 4, Insider Trading, Equity Compensation, Director Ownership